Photo taken from MiNK Therapeutics/LinkedIn
Feb 6, 2024, 14:34
Potential of iNKT cells to combat resistance to immune checkpoint inhibitors – MiNK Therapeutics
Quoting MiNK Therapeutics on LinkedIn:
“New publication in Oncogene spotlights a compelling case study of a durable response to our investigational iNKT cell therapy, agenT-797 in PD-1 refractory gastric cancer: ‘Overcoming Resistance to Programmed Cell Death Protein 1 (PD-1) Blockade with Allogeneic Invariant Natural Killer T-Cells (iNKT)’.
Read more about this case and the potential of iNKT cells to combat resistance to immune checkpoint inhibitors.
Thank you, Benedito A. Carneiro, MD, MS, and Matthew Hadfield, DO, for your collaboration on this important work.”
Source: MiNK Therapeutics/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 10:38
Dec 21, 2024, 10:35
Dec 21, 2024, 10:19
Dec 21, 2024, 09:22
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37